Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy
2021-001921-31Phase 4Active
- Sponsor
- Ghent University Hospital
- Start
- Sep 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dehydroepiandrosterone and Gynoflor in vaginal atrophy and breast cancer (3 arms), sponsored by Ghent University Hospital. Primary endpoint: Primary efficacy endpoint. Started Sep 2021; status: active.
02
Drugs
dehydroepiandrosteroneGynoflor
03
Conditions
vaginal atrophybreast cancer
Beyond the preview
Go deeper on 2021-001921-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001921-31.